RE: Covid, Worst still to come30 Jun 2020 14:19
Not being first to market almost certainly has an impact on the future success of the GDR product.
To displace existing products, the fact that our test has advantages over some of the others out there might not be enough. Maybe the advantages of our product aren't enough to disrupt. Maybe governments have already put in processes to mitigate against any shortcomings of existing products.
These other companies also have their foot in the door. They will have had time to increase production and had time to evolve their product like NCYT. I would suggest that governments looking for tests would use those in actual use elsewhere.
Look at India, they have approved almost 60 PCR tests, it's not being 1st to market, we aren't even 50th.
Given the above BBN, how can it be that none of that impacts the potential of the GDR product in any way?